Last updated: October 1, 2026
VENTAVIS, the inhaled iloprost product for pulmonary arterial hypertension, is a mature orphan drug with limited commercial growth prospects. Its original clinical value came from providing an inhaled prostacyclin-pathway treatment before newer oral and inhaled therapies expanded the category. Revenue declined as competition increased, treatment shifted toward longer-acting products, and the product’s patent and regulatory exclusivity expired. Standalone current revenue is not publicly reported by Johnson & Johnson, which acquired Actelion, the former commercial owner.
What is VENTAVIS and how does it work?
VENTAVIS contains iloprost, a synthetic prostacyclin analog administered by inhalation. It is approved for the treatment of pulmonary arterial hypertension, particularly functional class III disease, to improve exercise capacity and symptoms. The U.S. product is administered through a specialized nebulizer and is typically dosed six to nine times per day, depending on tolerability and clinical response (U.S. Food and Drug Administration [FDA], 2004).
Iloprost activates prostacyclin receptors, producing pulmonary vasodilation and inhibiting platelet aggregation and vascular smooth-muscle proliferation. The pharmacologic class includes:
| Product |
Active ingredient |
Route |
Commercial position |
| VENTAVIS |
Iloprost |
Inhaled nebulized solution |
Mature, declining product |
| TYVASO |
Treprostinil |
Inhaled solution |
Major inhaled competitor |
| TYVASO DPI |
Treprostinil |
Dry-powder inhalation |
Newer, more convenient formulation |
| REMODULIN |
Treprostinil |
Injection |
Parenteral prostacyclin therapy |
| ORENITRAM |
Treprostinil |
Oral |
Oral prostacyclin-pathway therapy |
| UPTRAVI |
Selexipag |
Oral |
Major oral prostacyclin-receptor pathway competitor |
VENTAVIS competes on established clinical use and physician familiarity. It is disadvantaged by frequent administration, device dependence, and competition from products with oral or dry-powder delivery.
When did VENTAVIS lose exclusivity?
VENTAVIS lost its most important exclusivity protections years ago.
| Milestone |
Date or status |
| U.S. approval |
December 29, 2004 |
| U.S. orphan-drug exclusivity |
Expired in December 2011 |
| Original product and compound patent protection |
Expired or no longer commercially decisive |
| Current patent-driven exclusivity |
No longer the primary barrier to entry |
| Regulatory category |
Small-molecule drug, not a biologic |
| Biosimilar exclusivity |
Not applicable |
The FDA approved VENTAVIS under NDA 021779. Its orphan-drug exclusivity provided seven years of protection from approval, subject to the orphan-drug framework in effect at that time (FDA, 2004; FDA, 2023).
The product’s long-term commercial protection depended more on brand recognition, specialized delivery equipment, physician familiarity, and reimbursement access than on unexpired composition-of-matter rights. Because iloprost is a small molecule, future competition would occur through abbreviated new drug applications rather than biosimilar applications.
What is the Orange Book status of VENTAVIS?
VENTAVIS is listed in the FDA’s Orange Book under NDA 021779. The commercial significance of the listing is limited because the product’s original exclusivity period has expired and no active patent estate is widely recognized as a substantial barrier to generic entry.
Orange Book considerations include:
- The reference product is iloprost inhalation solution.
- The relevant regulatory pathway for a competitor is generally an ANDA, subject to pharmaceutical-equivalence, bioequivalence, device, and product-quality requirements.
- A generic entrant may need to address the nebulizer or delivery configuration, not only the active ingredient.
- Device compatibility, dose uniformity, aerosol particle size, preservative profile, and container-closure performance can affect approval and substitution.
- An Orange Book patent listing, if active, would require a Paragraph IV or other applicable certification. No publicly prominent, current Paragraph IV dispute has defined the VENTAVIS market in the way that patent litigation has shaped other specialty drugs.
Patent expiration does not automatically produce generic entry. For a low-volume orphan product, the economic return may not justify development, clinical bridging, device validation, manufacturing scale-up, and payer contracting.
How many patents protect VENTAVIS?
The commercially relevant patent estate is limited. The underlying iloprost molecule is old, and the principal value of any remaining intellectual property would lie in formulation, inhalation-device, manufacturing, or use claims rather than basic compound protection.
| IP category |
Commercial assessment |
| Iloprost composition patent |
Expired or ineffective as a current market barrier |
| Method-of-use patents |
Any historical protection is unlikely to control broad PAH use today |
| Inhalation formulation patents |
Potentially relevant if valid and listed, but not the main market narrative |
| Nebulizer and delivery patents |
May protect specific devices or operating methods |
| Manufacturing know-how |
Could remain confidential and commercially useful |
| Trademark rights |
Protect VENTAVIS branding but do not prevent generic iloprost |
The main residual barrier is technical. A competing company must produce a stable inhalation solution and demonstrate consistent pulmonary delivery. This is more complex than launching a conventional oral tablet, although it is less difficult than developing a new biologic or implantable delivery system.
What formulation and device patents protect VENTAVIS?
VENTAVIS was designed for delivery through the I-neb AAD System and related nebulization equipment. The device delivers a metered dose of inhaled iloprost and forms part of the product’s use model.
Potentially relevant protection can include:
- The aqueous iloprost formulation.
- Concentration and dose-delivery parameters.
- Nebulizer operation and aerosol-generation methods.
- Device-drug compatibility.
- Container-closure and stability characteristics.
- Instructions governing treatment frequency and dose escalation.
These rights are narrower than a composition-of-matter patent. A generic developer could attempt to design around device claims by using a different nebulizer, formulation concentration, or delivery architecture. That strategy could create a product requiring separate device validation and potentially a regulatory pathway more complicated than a simple formulation copy.
What was VENTAVIS’s financial trajectory?
VENTAVIS was a small product within Actelion’s broader pulmonary hypertension portfolio. Actelion disclosed product-level sales during the years before its acquisition by Johnson & Johnson. Reported VENTAVIS revenue declined as the market moved toward newer products.
| Period |
Reported commercial direction |
| 2000s |
Growth as an established inhaled prostacyclin option |
| Early 2010s |
Mature orphan product with stable specialist use |
| 2014-2016 |
Decline as oral and competing inhaled therapies expanded |
| 2017 onward |
Product absorbed into Johnson & Johnson’s broader pharmaceutical reporting |
| Current public reporting |
No consistent standalone VENTAVIS revenue disclosure |
Actelion’s annual reports placed VENTAVIS revenue in the approximate range of CHF 80 million to CHF 100 million in the mid-2010s, with a downward trend. Exact figures varied by reporting year, currency, and geographic presentation (Actelion Pharmaceuticals Ltd., 2015, 2016).
The 2017 acquisition changed the visibility of the asset. Johnson & Johnson acquired Actelion’s commercial operations while separating Actelion’s research activities into Idorsia. VENTAVIS became a relatively minor product within a much larger Johnson & Johnson portfolio and was not generally reported as a separately material revenue line after the transaction (Johnson & Johnson, 2017).
Which companies challenge VENTAVIS commercially?
The strongest competitive pressure comes from products that address the same prostacyclin-pathway treatment need with fewer administration burdens.
United Therapeutics
United Therapeutics is the most important commercial competitor through TYVASO, TYVASO DPI, REMODULIN, and ORENITRAM. TYVASO provides inhaled treprostinil therapy, while TYVASO DPI offers dry-powder delivery and reduced device complexity. The company also markets oral and injectable prostacyclin-pathway products, allowing it to cover multiple stages of PAH treatment (United Therapeutics Corporation, 2023).
Johnson & Johnson
Johnson & Johnson controls several competing or adjacent PAH products, including Opsumit and Uptravi through its Janssen organization. This creates a portfolio-level substitution effect: a physician may choose an oral endothelin-receptor antagonist or oral prostacyclin-pathway therapy rather than prescribe inhaled iloprost.
Generic manufacturers
Generic competition is structurally possible but commercially uncertain. A generic manufacturer would face:
- A relatively narrow patient population.
- Specialized inhalation-device requirements.
- Potentially high development costs relative to annual sales.
- Reimbursement pressure after launch.
- Competition from better-known branded alternatives.
- The need to secure reliable iloprost supply and device manufacturing.
No major generic launch has publicly reshaped the U.S. VENTAVIS market through 2023.
What generic entry risks exist for VENTAVIS?
The risk is legally high but commercially moderate.
Legal risk is high because the principal exclusivity period has ended and iloprost is an established small molecule. A qualified generic manufacturer could pursue an ANDA if it can satisfy FDA requirements.
Commercial entry risk is lower because approval alone would not guarantee a viable launch. The market is specialized, branded competitors have broader treatment portfolios, and physicians may prefer newer delivery systems. A generic product could gain share through price discounts, but the addressable revenue base is much smaller than during VENTAVIS’s peak commercial period.
A likely generic launch would involve one of three models:
| Launch model |
Likely market effect |
| Same or closely comparable nebulized solution |
Direct price competition |
| Iloprost solution with a different nebulizer |
Partial substitution and device-driven differentiation |
| Hospital or specialty-pharmacy supply product |
Focused access strategy rather than broad retail substitution |
A Paragraph IV challenge would be relevant only if an unexpired, listed patent remained in force. The absence of a major public VENTAVIS patent dispute suggests that patent litigation is not the principal current market risk.
What is the FDA regulatory status of VENTAVIS?
VENTAVIS is an FDA-approved treatment for pulmonary arterial hypertension. The main regulatory issue is commercial availability rather than new clinical expansion.
The product’s regulatory position has several implications:
- It has a well-established safety and efficacy record.
- The label supports specialized PAH use rather than a broad cardiovascular indication.
- New indications would require clinical development and would face competition from established therapies.
- A generic would need to demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable FDA pathway.
- Device differences could affect the substitutability analysis.
VENTAVIS is not subject to biosimilar competition because iloprost is a chemically synthesized small molecule. The relevant competitive framework is generic substitution, therapeutic substitution, and portfolio switching.
What licensing deals affect VENTAVIS?
The principal corporate transaction was Johnson & Johnson’s 2017 acquisition of Actelion. The deal transferred Actelion’s commercial portfolio, including VENTAVIS, into Johnson & Johnson’s pharmaceutical operations. Actelion’s research pipeline was separated into Idorsia, which did not create a new, visible VENTAVIS growth platform (Johnson & Johnson, 2017).
No recent licensing transaction has materially changed VENTAVIS’s market profile. The product’s commercial trajectory is tied more closely to portfolio rationalization, lifecycle management, and PAH treatment substitution than to new external licensing.
What patent litigation and settlement agreements affect VENTAVIS?
No major publicly prominent patent litigation or Paragraph IV settlement has defined the VENTAVIS market through 2023. The absence of a large settlement is consistent with the product’s mature status, limited revenue base, and lack of a high-value remaining patent barrier.
Potential disputes would most likely concern:
- Formulation patents.
- Device compatibility.
- Inhalation methods.
- Product labeling.
- Manufacturing processes.
- Substitution or regulatory exclusivity issues.
These risks are narrower than the composition-of-matter disputes commonly seen with newer branded drugs.
How strong is the VENTAVIS patent estate?
The patent estate is weak as a current exclusivity platform and moderate as a technical barrier.
| Dimension |
Assessment |
| Compound protection |
Weak or expired |
| Orphan exclusivity |
Expired |
| Formulation protection |
Potentially relevant but narrow |
| Device protection |
Relevant to specific delivery systems |
| Manufacturing know-how |
Possible residual advantage |
| Litigation leverage |
Limited |
| Generic vulnerability |
Moderate to high over time |
| Commercial durability |
Driven by clinical familiarity, not patents |
The product’s defensibility is therefore operational rather than legal. Reliable supply, reimbursement relationships, physician familiarity, and patient continuity may delay displacement, but they do not create durable exclusivity.
What is the likely future market trajectory for VENTAVIS?
VENTAVIS is likely to remain a niche or declining product unless a manufacturer invests in a materially easier delivery system or secures a differentiated commercial position. The main market trends are unfavorable:
- PAH treatment is shifting toward oral therapies where clinically appropriate.
- Inhaled prostacyclin treatment is moving toward more convenient systems.
- TYVASO and TYVASO DPI strengthen United Therapeutics’ position in inhaled therapy.
- Johnson & Johnson’s own PAH portfolio reduces the strategic priority of an older inhaled product.
- Generic entry remains feasible if the commercial opportunity supports development.
- Product-specific revenue is unlikely to regain historical peak levels without a new formulation or device strategy.
The most plausible financial path is continued erosion, with revenue becoming immaterial within the parent company’s consolidated reporting. The asset may retain value in selected countries or specialist channels where treatment continuity and local availability matter, but global growth is unlikely.
Key Takeaways
- VENTAVIS is an inhaled iloprost treatment for pulmonary arterial hypertension.
- U.S. approval occurred in December 2004, and orphan-drug exclusivity expired in December 2011.
- The product is a small molecule and faces generic, not biosimilar, competition.
- Its original compound protection is no longer a meaningful commercial barrier.
- Device, formulation, manufacturing, and supply considerations are the remaining technical defenses.
- Actelion reported mid-2010s annual VENTAVIS revenue of roughly CHF 80 million to CHF 100 million, with decline.
- Johnson & Johnson acquired Actelion in 2017 and no longer reports VENTAVIS as a consistently separate material revenue line.
- TYVASO, TYVASO DPI, ORENITRAM, REMODULIN, UPTRAVI, and Opsumit drive competitive pressure.
- No major public Paragraph IV litigation or settlement has defined the product’s current market.
- The commercial outlook is mature to declining, with limited prospects for standalone revenue growth.
FAQs
Is VENTAVIS still commercially available?
Availability depends on country, distributor, and treatment channel. The product’s regulatory approval does not guarantee continuous commercial supply in every market.
Is iloprost the same as treprostinil?
No. Both act within the prostacyclin pathway, but iloprost and treprostinil are different active ingredients with different pharmacologic, dosing, and delivery profiles.
Can a generic company copy VENTAVIS?
A generic company may pursue an FDA approval pathway if it can satisfy formulation, quality, delivery-device, and equivalence requirements. Patent expiration removes the principal legal barrier, but technical and commercial barriers remain.
Does VENTAVIS have biosimilar risk?
No. VENTAVIS contains the chemically synthesized small molecule iloprost. Biosimilar regulation applies to biologic products, not conventional small-molecule drugs.
Which product is the closest commercial competitor to VENTAVIS?
TYVASO is the closest branded competitor because it is an inhaled prostacyclin-pathway treatment for PAH. TYVASO DPI increases the competitive disadvantage of VENTAVIS by offering a newer dry-powder delivery format.
References
Actelion Pharmaceuticals Ltd. (2015). Annual report 2015.
Actelion Pharmaceuticals Ltd. (2016). Annual report 2016.
Johnson & Johnson. (2017). Johnson & Johnson to acquire Actelion, creating a new global biopharmaceutical company. https://www.jnj.com
United Therapeutics Corporation. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
U.S. Food and Drug Administration. (2004). VENTAVIS (iloprost) inhalation solution prescribing information and approval materials.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
